These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38535994)

  • 41. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
    J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63.
    Tanaka N; Katayama S; Reddy A; Nishimura K; Niwa N; Hongo H; Ogihara K; Kosaka T; Mizuno R; Kikuchi E; Mikami S; Miyakawa A; Arenas E; Kere J; Oya M; Uhlén P
    Cancer Med; 2018 Dec; 7(12):6193-6204. PubMed ID: 30367559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.
    Pan YC; Chu PY; Lin CC; Hsieh CY; Hsu WY; Shyur LF; Yang JC; Chang WC; Wu YC
    Mol Oncol; 2024 Aug; 18(8):1866-1884. PubMed ID: 38750006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
    Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
    Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin.
    Zhu H; Yun F; Shi X; Wang D
    Int J Mol Med; 2015 Aug; 36(2):595-601. PubMed ID: 26080829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
    Grivas PD; Day KC; Karatsinides A; Paul A; Shakir N; Owainati I; Liebert M; Kunju LP; Thomas D; Hussain M; Day ML
    Mol Med; 2013 Nov; 19(1):367-76. PubMed ID: 24166682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
    Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
    Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
    Kashiwagi E; Inoue S; Mizushima T; Chen J; Ide H; Kawahara T; Reis LO; Baras AS; Netto GJ; Miyamoto H
    Br J Cancer; 2018 Jan; 118(2):213-223. PubMed ID: 29123257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors.
    Saga Y; Hashimoto H; Yachiku S; Iwata T; Tokumitsu M
    Int J Urol; 2004 Jun; 11(6):407-15. PubMed ID: 15157211
    [TBL] [Abstract][Full Text] [Related]  

  • 51. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
    Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
    J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
    Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
    Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
    Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
    Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1.
    Lin J; Zhang Q; Lu Y; Xue W; Xu Y; Zhu Y; Hu X
    PLoS One; 2014; 9(5):e98418. PubMed ID: 24846322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.
    Niwa N; Tanaka N; Hongo H; Miyazaki Y; Takamatsu K; Mizuno R; Kikuchi E; Mikami S; Kosaka T; Oya M
    Lab Invest; 2019 Nov; 99(11):1702-1713. PubMed ID: 31263157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
    Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TR3 modulates platinum resistance in ovarian cancer.
    Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
    Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
    Gil da Costa RM; Levesque C; Bianchi-Frias D; Chatterjee P; Lam HM; Santos C; Coleman IM; Ferreirinha P; Vilanova M; Pinto da Cunha N; Carvalho H; Moreira-Pais A; Faustino-Rocha A; Neto T; Batista da Costa J; Wright JL; Ferreira R; Oliveira PA; Mendes J; Bastos MMSM; Colaço B; Lopes C; Black PC; Sweeney CJ; Nelson PS
    Mol Oncol; 2023 Dec; 17(12):2709-2727. PubMed ID: 37533407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
    Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
    PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
    Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.